Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib in resectable NSCLC with MET alterations
NCT04926831Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label trial of capmatinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Novartis. Primary endpoint: Major Pathological Response Rate. Started Aug 2022; status: terminated.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04926831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926831.